Information Provided By:
Fly News Breaks for February 19, 2020
BBIO, QTWO, IHRT, WAFD, PRVL
Feb 19, 2020 | 10:25 EDT
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Prevail Therapeutics (PRVL) initiated with an Outperform at Oppenheimer. 2. Washington Federal (WAFD) initiated with an Equal Weight at Stephens. 3. iHeartMedia (IHRT) initiated with a Buy at Guggenheim. 4. Q2 Holdings (QTWO) initiated with a Neutral at Baird. 5. BridgeBio (BBIO) initiated with a Buy at Mizuho. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
News For PRVL;WAFD;IHRT;QTWO;BBIO From the Last 2 Days
IHRT
Jan 18, 2022 | 12:53 EDT
"Game On" is The Fly's weekly recap of the stories powering up or beating down video game stocks. NEW RELEASES: This... To see the rest of the story go to thefly.com. See Story Here
WAFD
Jan 18, 2022 | 08:19 EST
DA Davidson analyst Jeff Rulis raised the firm's price target on Washington Federal to $41 from $39 but keeps a Neutral rating on the shares. The company's Q1 results showed encouraging loan growth yet disappointing expense levels, the analyst tells investors in a research note. Rulis adds however that he expects Washington Federal's growth momentum and the bank's favorable rate positioning to outstrip the current expense headwinds.
WAFD
Jan 18, 2022 | 06:16 EST
Piper Sandler analyst Matthew Clark raised the firm's price target on Washington Federal to $37 from $34 and keeps a Neutral rating on the shares. The analyst increased estimates to reflect stronger loan growth and slower expense growth partly offset by much lower share buybacks.